Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma
Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma
复制标题
DOI：
10.2220/biomedres.41.149
复制
发表时间：
2020-01-01
影响因子：
1.2
通讯作者：
Sato, Yuichi
中科院分区：
文献类型：
--
作者：
Nagashio, Ryo;Kuchitsu, Yuki;Sato, Yuichi
NAP 1 L1是胚胎神经发生的关键调节因子，但其在肺癌中的作用尚未研究。本研究旨在探讨NAP 1 L1表达与非小细胞肺癌患者临床病理参数及预后的关系。为此，通过免疫组织化学评价肿瘤样品中NAP 1 L1的表达。NAP 1 L1表达与分化程度降低显著相关，（P = 0.00014），较高的病理TNM分期（P < 0.00001），淋巴结转移（P < 0.00001），肺内转移腺癌患者的淋巴管浸润（P = 0.00019）、血管浸润（P = 0.00008）和预后差（P = 0.0008）。此外，使用Cox比例风险模型的多变量分析证实，在调整其他临床病理因素后，NAP 1 L1表达增加死亡风险（HR = 2.46，95%CI，1.22-4.96）。此外，NAP 1 L1表达被确定为可切除I期肺腺癌患者的独立预后不良因素。NAP 1 L1-siRNA处理的肺腺癌衍生的A549细胞表现出显著的增殖、迁移和侵袭能力抑制。这些发现表明NAP 1 L1可能是肺腺癌的一种新的预测和预后标志物，特别是在I期肺腺癌患者中。
NAP1L1 is a key regulator of embryonic neurogenesis but its role in lung cancer remains unexplored. In this study, we investigated the relationship between NAP1L1 expression and the clinicopathological parameters and prognosis of non-small cell lung cancer patients. To this end, the expression of NAP1L1 in tumor samples was evaluated by immunohistochemistry. NAP1L1 expression was significantly associated with reduced differentiation (P = 0.00014), higher pathological TNM stages (P < 0.00001), lymph node metastasis (P < 0.00001), intrapulmonary metastasis (P = 0.02955), lymphatic invasion (P = 0.00019), vascular invasion (P = 0.00008) and poorer prognosis (P = 0.0008) of patients with adenocarcinoma. Moreover, multivariate analyses using the Cox-proportional hazards model confirmed that NAP1L1 expression increased the risk of death after adjusting for other clinicopathological factors (HR = 2.46, 95% CI, 1.22-4.96). Furthermore, NAP1L1 expression was identified as an independent poor prognostic factor in patients with resectable stage I lung adenocarcinoma. NAP1L1-siRNA-treated lung adenocarcinoma-derived A549 cells showed significant suppression of proliferation, migration, and invasion abilities. These findings suggest that NAP1L1 may be a novel predictive and prognostic marker in lung adenocarcinoma, particularly in those with stage I of the disease.